Clincosm LogoSign in Get a demo

Impact of COVID-19 on Psoriasis Practice

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT04581044
Collaborator
(none)
197
Enrollment
1
Location
1.2
Actual Duration (Months)
166.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

COVID-19 had a major impact on dermatology practice globally with special emphasis on chronic diseases e.g. psoriasis. The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis management.

This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian dermatologists.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    197 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Cross-Sectional
    Official Title:
    Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study
    Actual Study Start Date :
    Sep 17, 2020
    Actual Primary Completion Date :
    Oct 23, 2020
    Actual Study Completion Date :
    Oct 23, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19 [2-4 weeks]

    2. Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour [2-4 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Egyptian Dermatologists

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mona El-Kalioby Cairo Egypt 11351

    Sponsors and Collaborators

    • Cairo University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Mona El-Kalioby, Principal Investigator, Cairo University
    ClinicalTrials.gov Identifier:
    NCT04581044
    Other Study ID Numbers:
    • KAPU2020 10
    First Posted:
    Oct 9, 2020
    Last Update Posted:
    Jan 14, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mona El-Kalioby, Principal Investigator, Cairo University
    Psoriasis
    coronavirus
    Sars-Cov-2
    Additional relevant MeSH terms:
    COVID-19
    Psoriasis

    Study Results

    No Results Posted as of Jan 14, 2022